NEW YORK, Dec. 19, 2023 Anavex Life Sciences Corp. , a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and.
Anavex Life Sciences (AVXL) Received Agreement from the CHMP for the Submission of a Marketing Authorisation Application of Oral Blarcamesine for Alzheimer's Disease streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Anavex Life Sciences Corp. (AVXL) shares went up by 11% on Tuesday following the announcement that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has approved their oral blarcamesine for Alzheimer's disease, making it eligible for submission of a Union Marketing Authorisation application in the EU.
Anavex Life Sciences Corp. announced that the Committee for Medicinal Products for Human Use within the European Medicines Agency agreed that oral blarcamesine for Alzheimer s disease is eligible.